NCT04388124

Endothelin-1 Receptor Blockade in Resistant Hypertension

VASCULAR AND RENAL IMPACT OF ENDOTHELIN-1 RECEPTOR BLOCKADE IN PATIENTS WITH RESISTANT ARTERIAL HYPERTENSION

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 24 (estimated)
• Sponsor: University Hospital, Rouen · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The management of patients with resistant arterial hypertension, who are characterized by a very high cardiovascular risk, remains a major therapeutic issue. The use of endothelin-1 (ET-1) receptor antagonists, in addition to lowering blood pressure, may also improve endothelial function in these patients. The objective of this study is to assess the vascular impact of an ET-1 receptor antagonist on vascular function and systemic and central hemodynamics in patients with resistant arterial hypertension and ensure their good renal tolerance.

Conditions

• Resistant Hypertension

Interventions

Type	Name	Description
DRUG	Bosentan	vascular assesment Clinical exam urinary analysis blood results natriuresis and measured glomerular filtration rate
DRUG	Placebo	Placebo

Timeline

• Start date: 2021-10-20
• Primary completion: 2026-08-01
• Completion: 2026-08-01
• First posted: 2020-05-14
• Last updated: 2026-02-17

Locations

1 site across 1 country: France